Xanthon Inc.
This article was originally published in Start Up
Executive Summary
Molecular Diagnostics. Xanthon claims it is developing a platform technology that will allow target squences of DNA or RNA to be detected with far less handling than PCR now requires. The technology takes advantage of the electrochemical properties of DNA. Xanthon attaches a membrane to an electrode and probes to the membrane. If a target sequence is present in the sample exposed to the membrane, it will bind, or hybridize there.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.